Chardan lowered the firm’s price target on 4D Molecular (FDMT) to $28 from $30 and keeps a Buy rating on the shares. The firm is adjusting its model after the company’s Q4 earnings while noting that 4D Molecular is progressing with its phase 3 4FRONT-1 and 4FRONT-2 trials for 4D-150 in wet AMD, with topline data expected in the second half of 2027, while its interim phase 2b PRISM data has shown promising reductions in injection burden.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular price target lowered to $35 from $39 at RBC Capital
- Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating
- 4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position
- Optimistic Buy Rating for 4D-150 Driven by PRISM Study’s Promising Results in Treating Wet Age-Related Macular Degeneration
- 4D Molecular price target lowered to $30 from $39 at Chardan